Patent · US Active

Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer

US10399933B2 · kind B2 · utility

1Cited by

0References

13Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

James Aaron Balog · Lambertville, US
Weiwei Guo · Lawrenceville, US
Audris Huang · Princeton, US
Jay A. Markwalder · New London, US
Weifang Shan · Princeton, US
David K. Williams · Cinnaminson, US
Susheel Jethanand Nara · Mumbai, IN
Saumya Roy · Bengaluru, IN

Key dates

Filing date	Apr 1, 2016
Grant date	Sep 3, 2019
Priority date	—
Expiry date	Apr 1, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/08
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.